534 related articles for article (PubMed ID: 37916745)
1. Antioxidants for adults with chronic kidney disease.
Colombijn JM; Hooft L; Jun M; Webster AC; Bots ML; Verhaar MC; Vernooij RW
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD008176. PubMed ID: 37916745
[TBL] [Abstract][Full Text] [Related]
2. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Tunnicliffe DJ; Palmer SC; Cashmore BA; Saglimbene VM; Krishnasamy R; Lambert K; Johnson DW; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD007784. PubMed ID: 38018702
[TBL] [Abstract][Full Text] [Related]
3. Antioxidants for chronic kidney disease.
Jun M; Venkataraman V; Razavian M; Cooper B; Zoungas S; Ninomiya T; Webster AC; Perkovic V
Cochrane Database Syst Rev; 2012 Oct; 10(10):CD008176. PubMed ID: 23076940
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.
Natale P; Tunnicliffe DJ; Toyama T; Palmer SC; Saglimbene VM; Ruospo M; Gargano L; Stallone G; Gesualdo L; Strippoli GF
Cochrane Database Syst Rev; 2024 May; 5(5):CD015588. PubMed ID: 38770818
[TBL] [Abstract][Full Text] [Related]
5. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
6. Antiplatelet agents for chronic kidney disease.
Natale P; Palmer SC; Saglimbene VM; Ruospo M; Razavian M; Craig JC; Jardine MJ; Webster AC; Strippoli GF
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD008834. PubMed ID: 35224730
[TBL] [Abstract][Full Text] [Related]
7. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
Cooper TE; Teng C; Tunnicliffe DJ; Cashmore BA; Strippoli GF
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD007751. PubMed ID: 37466151
[TBL] [Abstract][Full Text] [Related]
9. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
[TBL] [Abstract][Full Text] [Related]
10. Synbiotics, prebiotics and probiotics for people with chronic kidney disease.
Cooper TE; Khalid R; Chan S; Craig JC; Hawley CM; Howell M; Johnson DW; Jaure A; Teixeira-Pinto A; Wong G
Cochrane Database Syst Rev; 2023 Oct; 10(10):CD013631. PubMed ID: 37870148
[TBL] [Abstract][Full Text] [Related]
11. Low protein diets for non-diabetic adults with chronic kidney disease.
Hahn D; Hodson EM; Fouque D
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD001892. PubMed ID: 33118160
[TBL] [Abstract][Full Text] [Related]
12. Low protein diets for non-diabetic adults with chronic kidney disease.
Hahn D; Hodson EM; Fouque D
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD001892. PubMed ID: 30284724
[TBL] [Abstract][Full Text] [Related]
13. Non-immunosuppressive treatment for IgA nephropathy.
Tunnicliffe DJ; Reid S; Craig JC; Samuels JA; Molony DA; Strippoli GF
Cochrane Database Syst Rev; 2024 Feb; 2(2):CD003962. PubMed ID: 38299639
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
Hara T; Hijikata Y; Matsubara Y; Watanabe N
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013424. PubMed ID: 34231877
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological interventions for heart failure in people with chronic kidney disease.
Lunney M; Ruospo M; Natale P; Quinn RR; Ronksley PE; Konstantinidis I; Palmer SC; Tonelli M; Strippoli GF; Ravani P
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD012466. PubMed ID: 32103487
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive agents for treating IgA nephropathy.
Natale P; Palmer SC; Ruospo M; Saglimbene VM; Craig JC; Vecchio M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD003965. PubMed ID: 32162319
[TBL] [Abstract][Full Text] [Related]
17. Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Hasegawa T; Nishiwaki H; Ota E; Levack WM; Noma H
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013109. PubMed ID: 33586138
[TBL] [Abstract][Full Text] [Related]
18. Calcium channel blockers for people with chronic kidney disease requiring dialysis.
Mugendi GA; Mutua FM; Natale P; Esterhuizen TM; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011064. PubMed ID: 33000470
[TBL] [Abstract][Full Text] [Related]
19. Interventions for weight loss in people with chronic kidney disease who are overweight or obese.
Conley MM; McFarlane CM; Johnson DW; Kelly JT; Campbell KL; MacLaughlin HL
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013119. PubMed ID: 33782940
[TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
